<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03313635</url>
  </required_header>
  <id_info>
    <org_study_id>AND-1-17</org_study_id>
    <nct_id>NCT03313635</nct_id>
  </id_info>
  <brief_title>Evaluation of Prealbumin Levels in Men With Low-T</brief_title>
  <official_title>Prealbumin (Transthyretin) Levels in Men With Low-T</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beckman Coulter, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beckman Coulter, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center study intended to evaluate prealbumin (transthyretin), a marker of
      anabolic metabolism, in men with androgen deficiency (Low-T). There is emerging evidence that
      prealbumin is an indicator of anabolic, versus catabolic, metabolism, and that lower levels
      may be associated with hypogonadism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 8, 2017</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prealbumin Levels</measure>
    <time_frame>1 day</time_frame>
    <description>Evaluation of prealbumin levels in subjects presenting for evaluation of possible late onset adult hypogonadism diagnosed with and without Androgen Deficiency (AD)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">19</enrollment>
  <condition>Testosterone Deficiency</condition>
  <arm_group>
    <arm_group_label>Men presenting with low-T</arm_group_label>
    <description>Men presenting with low-t will undergo a blood draw for evaluation of prealbumin levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Men presenting with low-T</intervention_name>
    <description>Evaluation of prealbumin levels.</description>
    <arm_group_label>Men presenting with low-T</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Frozen serum samples are retained for this study and possible future studies.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men between the ages of 40 and 75 presenting with signs/symptoms of low-T.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide responses to standard questionnaires administered to subjects

          -  Written Informed Consent obtained

          -  Male sex at birth

          -  ≥ 40 and ≤ 75 years of age

          -  Presentation to the clinic with symptoms suggestive of low testosterone such as loss
             of libido, erectile dysfunction, cognitive or mood disturbances, etc.

          -  Able and willing to provide blood specimens and follow study schedule

          -  A final diagnosis can be established (androgen deficient versus not androgen
             deficient)

        Exclusion Criteria:

          -  Previous exposure to exogenous T, DHEA, clomiphen citrate, or other Selective Estrogen
             Receptor Modulators, or OTC or herbals (Treatment Naïve)

          -  Use of opioid medication within 3 months prior to enrollment

          -  Serious psychiatric disease or uncontrolled medical illness, as suspected from medical
             history or clinical examination

          -  Use of any sex hormones or steroidal anabolic drug supplements (OTC or
             prescribed)(Treatment Naïve)

          -  Incapable of giving informed consent or complying with protocol or unwilling to comply
             with protocol requirements

          -  Diagnosis of prolactinoma
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male sex at birth</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Abraham Morgentaler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Men's Health Boston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Men's Health Boston</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>October 13, 2017</study_first_submitted>
  <study_first_submitted_qc>October 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2017</study_first_posted>
  <last_update_submitted>July 11, 2018</last_update_submitted>
  <last_update_submitted_qc>July 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prealbumin</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

